|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/09/21 Y-mAbs Therapeutics, Inc. 10-Q 6/30/21 76:7.2M Toppan Merrill Bridge/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 1.24M
2: EX-31.1 Certification -- §302 - SOA'02 HTML 28K
3: EX-31.2 Certification -- §302 - SOA'02 HTML 27K
4: EX-32.1 Certification -- §906 - SOA'02 HTML 23K
5: EX-32.2 Certification -- §906 - SOA'02 HTML 23K
12: R1 Document and Entity Information HTML 75K
13: R2 Consolidated Balance Sheets HTML 98K
14: R3 Consolidated Balance Sheets (Parenthetical) HTML 34K
15: R4 Consolidated Statements of Net Income/(Loss) and HTML 87K
Comprehensive Income/(Loss)
16: R5 Consolidated Statements of Changes in HTML 82K
Stockholders' Equity
17: R6 Consolidated Statements of Cash Flows HTML 87K
18: R7 Organization and Description of Business HTML 24K
19: R8 Basis of Presentation HTML 29K
20: R9 Summary of Significant Accounting Policies HTML 78K
21: R10 Product Revenue HTML 54K
22: R11 Net Loss Per Share HTML 54K
23: R12 Inventory HTML 38K
24: R13 Accrued Liabilities HTML 42K
25: R14 License Agreements and Commitments HTML 135K
26: R15 Stockholders' Equity HTML 30K
27: R16 Share-Based Compensation HTML 92K
28: R17 Related Party Transactions HTML 25K
29: R18 Income Taxes HTML 27K
30: R19 Other Benefits HTML 24K
31: R20 Gain From Sale of Priority Review Voucher HTML 25K
32: R21 Summary of Significant Accounting Policies HTML 105K
(Policies)
33: R22 Summary of Significant Accounting Policies HTML 59K
(Tables)
34: R23 Product Revenue (Tables) HTML 49K
35: R24 Net Loss Per Share (Tables) HTML 52K
36: R25 Inventory (Tables) HTML 39K
37: R26 Accrued Liabilities (Tables) HTML 41K
38: R27 License Agreements and Commitments (Tables) HTML 129K
39: R28 Share-Based Compensation (Tables) HTML 84K
40: R29 BASIS OF PRESENTATION - Accumulated deficit HTML 24K
(Details)
41: R30 BASIS OF PRESENTATION - Secondary public offering HTML 34K
(Details)
42: R31 BASIS OF PRESENTATION - Cash and cash equivalents HTML 24K
(Details)
43: R32 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 29K
Concentration of Credit Risk (Details)
44: R33 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair HTML 40K
Value Measurement (Details)
45: R34 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 44K
Revenue Recognition - License Revenue (Details)
46: R35 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 23K
Segment (Details)
47: R36 PRODUCT REVENUE - Discounts and Allowances HTML 58K
(Details)
48: R37 PRODUCT REVENUE - Concentrations (Details) HTML 33K
49: R38 NET LOSS PER SHARE - Basic and diluted (Details) HTML 47K
50: R39 NET LOSS PER SHARE - Anti-dilutive securities HTML 23K
(Details)
51: R40 Inventory (Details) HTML 28K
52: R41 Accrued Liabilities (Details) HTML 36K
53: R42 LICENSE AGREEMENTS AND COMMITMENTS - MSK, CD33 and HTML 65K
MabVax License Agreement (Details)
54: R43 LICENSE AGREEMENTS AND COMMITMENTS - Other HTML 40K
agreements (Details)
55: R44 LICENSE AGREEMENTS AND COMMITMENTS - Lease HTML 60K
agreements (Details)
56: R45 LICENSE AGREEMENTS AND COMMITMENTS - Lease costs HTML 31K
(Details)
57: R46 LICENSE AGREEMENTS AND COMMITMENTS - Lease HTML 38K
maturities (Details)
58: R47 LICENSE AGREEMENTS AND COMMITMENTS - Lease term HTML 26K
and discount rate (Details)
59: R48 STOCKHOLDERS' EQUITY - Authorized, Common and HTML 40K
Preferred Stock (Details)
60: R49 STOCKHOLDERS' EQUITY - Stock grant agreements with HTML 79K
non-employees (Details)
61: R50 STOCKHOLDERS' EQUITY - Issuance of common stock HTML 38K
(Details)
62: R51 SHARE-BASED COMPENSATION - 2015 Plan (Details) HTML 31K
63: R52 SHARE-BASED COMPENSATION - 2018 Plan (Details) HTML 41K
64: R53 SHARE-BASED COMPENSATION - Stock option expense HTML 34K
(Details)
65: R54 SHARE-BASED COMPENSATION - Stock option activity HTML 64K
(Details)
66: R55 SHARE-BASED COMPENSATION - Stock option HTML 28K
unrecognized compensation (Details)
67: R56 SHARE-BASED COMPENSATION - Restricted Stock Unit HTML 62K
Activity (Details)
68: R57 Related Party Transactions (Details) HTML 35K
69: R58 INCOME TAXES - Expense (Details) HTML 35K
70: R59 INCOME TAXES - Uncertain tax positions (Details) HTML 23K
71: R60 Other Benefits (Details) HTML 29K
72: R61 Gain From Sale of Priority Review Voucher HTML 34K
(Details)
74: XML IDEA XML File -- Filing Summary XML 135K
11: XML XBRL Instance -- ymab-20210630x10q_htm XML 1.59M
73: EXCEL IDEA Workbook of Financial Reports XLSX 85K
7: EX-101.CAL XBRL Calculations -- ymab-20210630_cal XML 130K
8: EX-101.DEF XBRL Definitions -- ymab-20210630_def XML 488K
9: EX-101.LAB XBRL Labels -- ymab-20210630_lab XML 1.13M
10: EX-101.PRE XBRL Presentations -- ymab-20210630_pre XML 847K
6: EX-101.SCH XBRL Schema -- ymab-20210630 XSD 162K
75: JSON XBRL Instance as JSON Data -- MetaLinks 325± 478K
76: ZIP XBRL Zipped Folder -- 0001558370-21-010959-xbrl Zip 297K
Exhibit 31.2
CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Bo Kruse, certify that:
| 1. | I have reviewed this quarterly report on Form 10-Q of Y-mAbs Therapeutics, Inc.; |
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
| 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
| 4. | The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
| a. | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
| b. | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
| c. | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
| d. | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
| 5. | The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
| a. | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
| b. | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
| | ||
Dated: August 9, 2021 | By: | /s/ Bo Kruse | |
| | Name: | |
| | Title: | EVP, Chief Financial Officer |
| | | (Principal Financial Officer) |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 8/9/21 | |||
| For Period end: | 6/30/21 | 4 | ||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/06/21 Y-mAbs Therapeutics, Inc. 10-Q 3/31/21 76:6.3M Toppan Merrill Bridge/FA 11/05/20 Y-mAbs Therapeutics, Inc. 10-Q 9/30/20 68:6.7M Toppan Merrill Bridge/FA 9/26/18 Y-mAbs Therapeutics, Inc. 8-K:5,7,9 9/25/18 4:284K Toppan Merrill/FA 8/24/18 Y-mAbs Therapeutics, Inc. S-1 31:12M Toppan Merrill-FA |